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In vitro DNA binding results from a series of E1 proteins containing amino-terminal or carboxy-terminal
truncations indicated that sequences between amino acids 121 and 284 were critical for origin binding.
Additional binding experiments with E1 proteins containing internal, in-frame insertions or deletions con-
firmed the importance of the region defined by truncated E1 proteins and also demonstrated that downstream
sequences were not required for binding activity in the context of the full-length E1 protein. On the basis of
mapping results from the E1 mutants, a clone (pE1121–311) was constructed that expressed E1 amino acids
within the approximate boundaries of the critical sequences for DNA binding. The E1121–311 protein retained
origin-specific DNA binding, confirming that this region was not only necessary but was also sufficient for
origin recognition. In addition to origin binding, E1121–311 bound E2 protein in a cold-sensitive manner.
Therefore, DNA binding and E2 binding activities colocalize to a 191-amino-acid functional domain derived
from the amino-terminal half of the E1 protein. Finally, three E1 proteins with mutations in this region all
lacked DNA binding activity and were all defective for in vivo replication. Two of these E1 mutants retained E2
binding capability, demonstrating that origin recognition by E1 is critical for replication and cannot neces-
sarily be rescued by an interaction with E2 protein.
The bovine papillomavirus type 1 (BPV-1) E1 protein is an
essential viral DNA replication factor that is both an origin
recognition protein (5, 6, 13, 17, 18, 20) and an ATP-depen-
dent helicase (14, 21). E1 binds to an 18-bp inverted repeat
element (5) and presumably initiates DNA replication both by
unwinding the origin duplex DNA and by recruiting cellular
replication factors such as DNA polymerase a (3, 11) to the
initiation complex. In vitro, E1 alone is sufficient to initiate
replication (3), but in vivo the viral full-length E2 transcrip-
tional activator protein is also absolutely required (16). E1 can
form complexes with the E2 protein (2, 8, 15, 20), and both
binding to and unwinding of origin DNA by E1 is enhanced by
these cooperative interactions with E2 (4, 9, 13, 20). Conse-
quently, the replication function of E1 appears dependent
upon both protein-DNA and protein-protein contacts. Defini-
tion of the regions of E1 involved in each of these activities will
facilitate our understanding of how protein-DNA complexes
assemble to mediate replication initiation. Previous studies
have begun the mapping of both the DNA binding domain (12,
15) and the E2 interaction domain(s) of E1 (1, 8, 12, 15) but
have yielded partially conflicting results. We have now refined
the mapping of the DNA binding domain and further demon-
strate that this isolated domain is capable of both binding
origin DNA and interacting with the E2 protein.
Construction of E1 deletion mutants. Previously, we showed
that a bacterially expressed form of the E1 protein (RecA-E1)
exhibited site-specific DNA binding to the BPV-1 origin (5,
18). The RecA-E1 protein (designated 1700T in this report)
consists of E1 amino acids 1 to 586 with an amino-terminal tag
of 35 amino acids derived from the amino terminus of the
RecA protein (19). To localize the DNA binding domain of
1700T we constructed a set of clones expressing truncated
forms of the 1700T protein. Carboxy-terminal truncations were
created by insertion of a translation termination linker into
the pGE1700T vector as previously described (7). Amino-ter-
minal truncations were constructed from either the parental
pGE1700T clone (clone N1) or from translation termination
linker derivatives of pGE1700T (clones N2, N3, and N5) by
removal of an appropriate restriction digestion fragment fol-
lowed by religation. The last amino-terminal truncation, clone
N4, was constructed by de novo cloning of a PCR-generated
fragment of the E1 gene into the pGE vector. Protein produc-
tion by each clone was assessed by Western blotting with an-
ti-E1 sera directed against either the carboxy (serum 5996) or
amino terminus (serum 5997) of E1. Each of the constructs
expressed a soluble protein of the correct predicted size that
was reactive with the appropriate anti-E1 serum (data not
shown). The E1 amino acids expressed from each construct are
summarized in Fig. 1C.
Evaluation of the DNA binding ability of E1 mutants. The
origin binding capability of each truncated E1 protein was
evaluated by an immunoprecipitation assay as previously de-
scribed (5, 6). In brief, bacterial extracts lacking or containing
E1 proteins were incubated with an equimolar mixture of an
origin-positive (256-bp) and an origin-negative (151-bp) DNA
fragment in 0.01 M Tris-HCl (pH 7.0), 150 mMNaCl, 0.01 mM
EDTA, and 5 mg of sheared salmon sperm DNA per ml. The
volume of each extract used was adjusted to provide equivalent
amounts of E1 protein as detected by Western blotting. The
256- and 151-bp DNA fragments were generated by PCR am-
plification and radiolabeled by incorporation of [a-32P]TTP
during the amplification. After 30 min at 258C, E1 proteins
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were precipitated with the appropriate anti-E1 serum and pro-
tein A-Sepharose. Coprecipitated DNA fragments were ex-
tracted in Tris-borate-EDTA sample buffer (89 mM Tris, 89
mM boric acid, 2.5 mM EDTA, 10% glycerol, 2.7% xylene
cyanol, 2.4% bromophenol blue, 2% sodium dodecyl sulfate
[SDS]) and analyzed on 8% polyacrylamide gels (Fig. 1A and
B).
The specificity of the DNA binding assay is demonstrated by
the observation that neither DNA fragment was bound either
by an extract lacking E1 protein (374 lanes) or when the 1700T
extract was precipitated with a preimmune serum (PI lanes).
Furthermore, when the 1700T extract was precipitated with
either anti-E1 serum 5996 or 5997, only the origin-containing
fragment was bound (IM lanes in Figs. 1A and 1B). Under
these same reaction conditions, deletion of amino acids 1 to
120 did not impair the origin-specific DNA binding ability of
E1 (clone N2) but removal of amino acids 1 to 272 (clone N3)
or more (clones N4 and N5) completely abolished binding
activity (Fig. 1A). These results map the amino-terminal
boundary of the DNA binding domain to between amino acids
121 and 273; this is consistent with a previous observation that
an E1162–422 protein retained origin binding activity (12).
Analysis of the carboxy-terminal E1 truncations revealed
that E11–395 (clone 1.49), E11–367 (clone 1.65), and E11–324
(clone 21A) all retained origin-specific DNA binding activity.
Truncation to amino acid 286 (clone 44.4) produced an E1
protein that bound very weakly but that was still origin specific,
while further truncation to residue 256 (clone 93.4) eliminated
DNA binding completely. From these results it is clear that
sequences downstream from amino acid 324 are not absolutely
necessary for origin binding. The dramatic reduction in binding
that occurred between clones 21A and 44.4 also suggests that
the functional carboxy-terminal boundary of this domain is
between amino acids 286 (clone 44.4) and 324 (clone 21A).
Note, however, that all the carboxy-terminal truncations bound
less origin DNA than that bound by the 1700T protein. This
may indicate that sequences in the carboxy terminus can con-
tribute directly to origin binding or alternatively that they in-
fluence the overall functional stability of the E1 protein.
The carboxy-terminal boundary that we determined is con-
sistent with the previous observation that an E11–299 protein
retained origin binding activity (15) but is in contrast to the
recent results of Sarafi and McBride that an E11–328 protein
lacked origin binding activity (12). Furthermore, Sarafi and
McBride showed that an E11–378 and an E1162–422 protein
bound the origin but that an E1162–378 protein did not (12).
These results imply that sequences beyond amino acid 328 are
critical for origin binding but that the exact sequences required
are somewhat dependent on the overall amino acid content of
the E1 construct.
To address the contribution of downstream residues in the
context of our 1700T protein, we constructed a series of inter-
nal, in-frame deletion and insertion mutations by the previ-
ously described procedure of Ludes-Meyers and Wilson (7).
Thirteen mutants were constructed throughout the region of
E1 from amino acid 197 to 487 (Fig. 2A), and their specific
amino acid changes are listed in Table 1. Expression of each
mutant E1 protein was verified by Western blotting (data not
shown), and each was tested for DNA binding as was done for
the truncation mutants. The three mutants with alterations in
the E1 sequence upstream of amino acid 300 (clones 15.2-64,
26.7-1, and 44.4-29) were completely defective for origin bind-
ing, confirming the importance of the amino-terminal region of
E1 for DNA binding. Conversely, all 10 of the downstream
mutants retained origin-specific DNA binding ability, indicat-
ing that there was no absolute requirement for these sequences
in the context of a full-length E1 protein.
The combined DNA binding results from the truncation
mutations and the in-frame, internal mutations defined a re-
gion between, approximately, amino acids 121 and 300 as con-
taining the E1 sequences necessary for origin binding. To de-
termine if this region was also sufficient for origin binding we
constructed clone E1121–311. Truncation mutant N2 was di-
gested with BstBI plus BstEII, and the 935-bp fragment con-
taining BPV-1 nucleotides 1470 to 2405 was removed. This
fragment was replaced with the corresponding fragment de-
rived from a translation termination mutant (6a) containing
stop codons after nucleotide 1783. The resultant construct was
expected to express E1 amino acids 121 to 311, and a product
with the correct molecular weight was detected by Western
FIG. 1. DNA binding by E1 truncation mutants. French press extracts were
prepared as previously described (18) from cells expressing the parental
RecA-E1 fusion protein (1700T lanes), cells lacking E1 (374 lanes), or cells with
the E1 truncation indicated above each lane. DNA binding with the extracts was
performed as described in the text. Extracts containing truncated E1 proteins or
no E1 protein were precipitated with anti-E1 serum 5996 (A) or anti-E1 serum
5997 (B). Extracts containing the 1700T E1 protein were precipitated with these
same two antisera (IM lanes) or preimmune serum (PI lanes). Lanes marked M
show the results for a sample of the input DNA consisting of a fragment con-
taining the BPV origin (256 bp) and a fragment lacking the origin (151 bp). (C)
A summary of the amino acids present in the various truncated proteins and of
their DNA binding results.
VOL. 71, 1997 NOTES 849
 o
n
 Septem
ber 12, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
blotting (Fig. 3A). E1121–311 was fully active for origin-specific
DNA binding (Fig. 3B), confirming that the critical E1 struc-
tural features for origin recognition reside in this 191-amino-
acid region.
E2 binding by E1 proteins. In addition to its origin binding
ability, E1 protein forms specific complexes with the E2 pro-
tein (1, 8, 12, 15). Since E2 enhances DNA binding by E1 (9,
13, 20), we asked whether or not our isolated DNA binding
domain (E1121–311) could still interact with the E2 protein in
vitro. A fragment containing the E2 coding region was gener-
ated by PCR amplification of pdBPV-1 with primers contain-
ing a BamHI site (primer 1, 59-GTATGGATCCTTGACGA
GGAGGAGGATAGTG-39; primer 2, 59-ATAGGGATCCTC
AGAAGTCCAAGCTGGCTGT-39). The amplified fragment
containing BPV-1 nucleotides 2581 to 3837 was digested with
BamHI and cloned into the BamHI site of the pRSET-A vec-
tor (InVitrogen). A resultant clone was designated pRSET-E2
and was confirmed by DNA sequencing. E2 RNA was pro-
duced by in vitro transcription of purified pRSET-E2 DNA in
the Ribomax system (Promega, Inc.) under standard condi-
tions specified by the manufacturer; control luciferase RNA
was synthesized in parallel reactions. Radiolabeled E2 and
luciferase proteins were produced by incorporation of [35S]me-
thionine (.1,000 Ci/mmol; New England Nuclear) during in
vitro translation of their respective RNAs with the Promega
rabbit reticulocyte lysate system. The in vitro-translated prod-
ucts were analyzed by electrophoresis on an 8% polyacryl-
amide-SDS gel and are shown in Fig. 3C (lanes 1 and 2). Each
translation reaction yielded a predominant radiolabeled prod-
uct of the predicted size for the full-length E2 or luciferase
proteins, as well as several shorter products that are most likely
premature termination products. The identity of the E2 prod-
uct was further confirmed by immunoprecipitation with an
anti-E2 monoclonal antibody (data not shown).
To assess E2 interactions with the amino terminus of E1,
extracts containing E1121–311 or the three amino-terminal re-
gion E1 mutants (15.26-1, 26.7-3, and 44.4-29) were immuno-
precipitated with anti-RecA serum and protein A-Sepharose
as previously described (18). The washed immunoprecipitates
were resuspended in 15 ml of 50 mM HEPES (pH 7.6)–0.01%
Nonidet P-40 containing either the in vitro-translated E2 or
luciferase proteins. Reactions were incubated for 1 h at either
room temperature or 48C, and all subsequent wash steps were
conducted at the same temperature as that of the initial incu-
bation. After incubation the beads were collected by centrifu-
gation for 1 min, washed three times with 1.0 ml of buffer A (50
mM HEPES [pH 7.6], 1.0 mM EDTA, 0.2 M NaCl, 0.5%
Nonidet P-40), and washed once with 1.0 ml of 50 mM HEPES
[pH 7.6]–1.0 mM EDTA. Bound proteins were extracted with
20 ml of SDS gel sample buffer at 1008C for 2 min, and the
extracted material was analyzed on an 8% polyacrylamide-SDS
gel (Fig. 3C). Under these conditions both bacterially ex-
pressed (1700T) and baculovirus-expressed E1 (Fig. 3C, lanes
6 and 7) bound E2 protein. The presence of E2 in the immu-
nocomplex was E1 dependent since no associated E2 was ob-
served when the initial immunoprecipitation step was per-
formed with preimmune serum (data not shown), when an
extract lacking E1 protein was used (data not shown), or when
the 26.7-1 E1 mutant was used (see below). When incubated at
room temperature, E1121–311 was also capable of binding the
E2 protein but not the control luciferase protein (Fig. 3C, lanes
4 and 5). Consequently, the isolated DNA binding domain
does retain the ability to recognize and specifically bind the E2
protein. Interestingly, this interaction is cold sensitive, and the
E1-E2 complex could not be detected at 48C (lane 3). A similar
observation that the amino-terminal E2 interaction domain is
cold sensitive was reported previously by Thorner et al. (15)
and Benson and Howley (1) for BPV-1 E1 and more recently
for human papillomavirus type 33 E1 by Mu¨ller and Sapp (10).
To further analyze the interaction between E2 and E1, E2
binding by the three amino-terminal region mutants was
tested. All three mutants lack origin binding ability, yet mu-
tants 15.26-1 and 44.4-29 were competent for E2 binding while
mutant 26.7-1 was completely defective (Fig. 3C, lanes 8 to 10).
The E1 26.7-1 mutation is located at amino acid 277, and the
failure of this mutant E1 to bind E2 is consistent with the
boundaries of the E2 interaction domain defined by E1121–311.
However, the location of the 26.7-1 mutation is between the
15.26-1 and 44.4-29 mutations; this suggests that while the E2
binding and origin recognition activities of E1 overlap, the
TABLE 1. Amino acid sequence of in-frame E1 mutants
Clone Sequencea
15.2-64.............................................192WVLAVF(lvav)GLAEVF203
26.7-1...............................................271SAALFW(slfw)FKSSLS282
44.4-29.............................................280SLSPAT-KHGALP292
24-43................................................366HYLRAE----SMPAYI382
2.23-11.............................................369LRAETQ-----(e)AYIKAA385
a1-5..................................................371AETQAL-------(a)ARCKLA389
2.3-33...............................................379PAYIKA------(k)GEGSWK396
1.49-1...............................................392EGSWKS------YQNIEL409
3.26-84.............................................406NIELIT----LKLWLK421
2.68-24.............................................439KSMLCN--(lc)IHFLGG452
80A-1...............................................455LSFANH-------(lv)SLADTR473
15.3-61.............................................473RAALVD--------YFDTYL492
1.68-70.............................................481THACWR--------------VSIDRK506
a The wild-type E1 amino acid sequence is shown in uppercase letters. Inserted
amino acids are shown in parentheses in lowercase. Each hyphen represents a
deleted amino acid. Numbers at each end of the sequence refer to the original
wild-type E1 amino acids.
FIG. 2. DNA binding by E1 proteins with internal, in-frame deletions and
insertions. (A) A diagram showing the relative locations of the 13 mutations in
the E1 open reading frame. The actual sequence changes for each mutant are
shown in Table 1. (B) For each E1 mutant shown in panel A extracts were
prepared and assayed for DNA binding with serum 5996 as described in the
legend for Fig. 1. Identical results were obtained with serum 5997 (data not
shown). Lanes M and 1700T correspond to lanes M and 1700T IM in Fig. 1A.
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region required for E2 binding is smaller than that needed for
origin recognition.
DNA replication activity of E1 mutants. The above studies
confirmed the importance of the amino-terminal portion of E1
for origin recognition in vitro. To determine if origin binding is
required for E1-dependent DNA replication, the mutations in
clones 15.2-64, 26.7-1, and 44.4-29 were constructed back into
the context of the viral genome (in clone pdBPV-1) and the
mutant BPV-1 genomes were tested for transient in vivo rep-
lication as previously described (17). All three mutations ren-
dered BPV-1 unable to replicate (Fig. 4 and data not shown).
This replication defect was observed at 32, 37, and 398C, in
contrast to the wild-type pdBPV-1, which replicated efficiently
at all three temperatures. The inability of 15.2-64 and 44.4-29
to replicate even though they could bind E2 indicates that E2
binding alone is insufficient for replication function.
The results presented in this study localize the boundaries of
the functional DNA binding domain of the BPV-1 E1 protein
to a 191-amino-acid region encompassing residues 121 to 311
of the full-length E1 protein. This is the smallest E1 polypep-
tide to date that still retains origin-specific binding activity, but
the actual essential domain could be even smaller. The car-
boxy-terminal boundary of the functional domain is fairly well
established and must be in the vicinity of amino acid 300 since
no origin binding activity has been demonstrated for any E1
protein truncated upstream of amino acid 284 (12, 15). How-
ever, the amino-terminal boundary is less well defined. An
E1162–422 protein has been shown to retain origin binding ac-
tivity (12), suggesting that sequences between amino acids 121
and 162 may not be critical, though this has not been directly
tested. Additional deletion and internal mutations will be re-
quired to more completely define the amino-terminal bound-
ary of the minimal DNA binding domain. Nonetheless, the
results presented here indicate that it is possible to isolate the
DNA binding domain of E1 as an independent polypeptide
consisting of less than one-third of the total E1 sequence.
In addition to origin binding activity, the E1121–311 protein
retained the ability to complex with the E2 protein at room
temperature but not at 48C. This is consistent with earlier
reports that an E11–423 protein (15) and an E11–222 protein (1)
bound E2 in a cold-sensitive fashion. Surprisingly, our 26.7-1
mutant failed to bind E2 even though this mutation is at amino
acid 277, which is not included in the active E11–222 protein.
However, we have found that an E11–286 protein (clone 44.4)
binds E2 while an E11–256 protein (clone 93.4) does not (data
not shown), which is consistent with the results for the 26.7-1
mutant. The explanation for this difference in the apparent
C-terminal boundary of the E2 interaction domain observed
for the various E1 truncation mutants is unknown but may
reflect conformational differences specific to the constructs
being tested or differences in the sensitivities of assays used. In
either case, the cold-sensitive character of this amino-terminal
E2 interaction domain of E1 has now been observed by several
groups and may explain the previously reported failure of an
E11–378 protein to bind E2, since the assay appeared to include
an immunoprecipitation step at 48C (12). Therefore, the com-
bined evidence from available studies is strongly supportive of
a functional E2 interaction domain in the amino-terminal re-
gion of the E1 protein. The location of this E2 interaction
domain is overlapping with but not coincident with the se-
quences required for origin-specific DNA binding activity.
Note, however, that the presence of this amino-terminal E2
interaction domain does not preclude the existence of other
FIG. 4. In vivo transient replication of BPV-1 genomes with wild-type or
mutant E1 genes. Shown are the in vivo replication results for wild-type (wt),
pdBPV-1 (lanes 1 to 3), and the 26.7-1 and 44.4-29 mutants (lanes 4 to 9). Each
DNA was BamHI digested prior to electroporation to liberate the BPV-1 se-
quences from the vector sequences. After electroporation of each DNA (5 mg),
recipient C127 cells were maintained at either 32, 37, or 398C for 72 h. For all
samples, low-molecular-weight DNAs were harvested and digested with BamHI
and DpnI prior to blotting with radiolabeled pdBPV-1. Lanes 10 and 11 show
results for 20 and 200 pg, respectively, of the BamHI-digested pdBPV-1. The
upper bands in these marker lanes represent the BPV-1 genome, and the lower
bands represent the vector genome.
FIG. 3. Expression, DNA binding, and E2 binding by the various E1 proteins. (A) Western blot of extracts lacking E1 (374), expressing an amino-terminal truncation
mutant (N3), and expressing the E1121–311 clone. Anti-RecA was used as the primary serum for this blot. The N3 and the E1121–311 proteins are indicated by arrows,
and molecular mass markers (in kDa) are on the left. The prominent band present in all three lanes is the endogenous RecA protein. (B) E1121–311 was assayed for
DNA binding as described in the legend for Fig. 1. (C) Binding of E1 proteins to E2 in vitro was performed as described in the text with the bacterial extracts containing
E1 proteins indicated above the lanes, except for lane 6 which represents baculovirus-expressed E1 protein purified from SF9 cells (generously provided by M. Lentz,
Texas A&M University). Binding reactions included either the in vitro-translated (IVT) control luciferase protein (C lanes) or the pRSET-E2 protein (E2 lanes) and
were performed at 48C or room temperature (RT) as indicated (lanes 3 to 10). All precipitations were performed with either anti-RecA serum (lanes 3 to 5) or anti-E1
serum 5996 (lanes 6 to 10). Lanes 1 and 2 represent samples of the input IVT proteins that were not subjected to the binding assay. Molecular mass markers (in kDa)
are on the left.
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regions of E1 that could also interact with the E2 protein (8,
12, 15).
The studies presented here also demonstrate that origin
binding is a critical requirement for E1 function in replication.
Three E1 mutants lacking in vitro origin recognition activity
were all completely defective for transient in vivo replication.
Two of these mutants were still capable of binding E2 in vitro,
indicating that E1-E2 interactions alone are not necessarily
sufficient to rescue defective origin binding by E1.
X.L. and J.H.L. contributed equally to this study.
This study was supported by grants from the Texas Advanced Re-
search Project and by PHS grant CA56699 from the National Cancer
Institute.
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